How Much Does Home Infusion Therapy Cost?

Home infusion therapy typically costs far less than receiving the same treatment in a hospital, but the absolute dollar amount varies enormously depending on the drug, the condition being treated, and how long therapy lasts. Studies consistently find savings ranging from roughly $100 to nearly $3,000 per treatment course when care moves from a hospital outpatient department to the home. The catch is that “home infusion” covers everything from a short course of antibiotics to years of immunoglobulin replacement or parenteral nutrition, so a single price tag is impossible. What the evidence does make clear is that the setting of care itself is one of the biggest cost drivers, often mattering as much as which drug is being infused.

The Cost Gap Between Home and Hospital

The most consistent finding in the home infusion literature is that receiving treatment at home or in a non-hospital alternative site costs substantially less than getting the same infusion in a hospital outpatient department. A review of the evidence found that home infusion costs were significantly lower than medical-setting infusion costs, with savings between roughly $1,900 and $3,000 per treatment course.¹ A large matched cohort analysis of more than 52,000 infusions across multiple chronic conditions confirmed that outpatient costs were about 42% higher when patients were treated in a hospital outpatient department compared with alternative sites of care, with no meaningful difference in emergency department visits or hospital admissions between groups.²

That 42% gap exists because hospitals layer facility fees, overhead charges, and administrative costs on top of the drug itself. When you receive an infusion in a hospital outpatient department, you are paying not just for the medication and the nurse’s time but also for a share of the building, the equipment, the regulatory compliance infrastructure, and the broader hospital staffing model. Move the same nurse and the same drug into your living room, and most of those charges disappear. The drug cost stays roughly the same, the nursing time is comparable, but the facility piece of the bill shrinks dramatically.

Intravenous Antibiotics at Home

One of the oldest and best-studied forms of home infusion is outpatient parenteral antibiotic therapy. If you have a serious bone, joint, or bloodstream infection that requires weeks of IV antibiotics, staying in the hospital for the full course is both miserable and expensive. Home antibiotic therapy was one of the first areas where the cost advantage of home infusion was demonstrated convincingly.

A study of a Medicare managed care program found that the average cost per day of home IV antibiotic therapy was about $122, compared with roughly $800 per day for hospital acute care and about $540 per day for a skilled nursing facility.³ That is not a small difference. Even at the lower end, moving care home cut daily costs by more than 75%. Another study found a mean savings of at least $112 per day for each day of home therapy provided, and the reduced bed use freed up hospital capacity for dozens of additional patients annually.⁴

For patients with infections requiring extended courses, the savings compound quickly. A cost analysis of patients treated for osteomyelitis found that the total cost of therapy combining initial inpatient care and subsequent home infusion was about $58,000, compared with an estimated $98,000 if all therapy had been provided in the hospital.⁵ That represents roughly a 40% reduction for a single treatment episode. For a condition that often requires four to six weeks of IV antibiotics, those daily cost differences translate into five-figure savings per patient.

Immunoglobulin Replacement Therapy

Immunoglobulin therapy is one of the most expensive categories of home infusion and also one where the home-versus-clinic cost difference is most dramatic. Patients with primary or secondary immune deficiencies often need regular immunoglobulin infusions for life, which means the cumulative cost exposure is enormous. Two main delivery options exist: intravenous immunoglobulin given in a clinic by a nurse, and subcutaneous immunoglobulin that patients can learn to self-administer at home.

The administration cost difference between those two routes is striking. A population-based study in Alberta, Canada, found that the average administration cost per patient-year of self-administered subcutaneous immunoglobulin was roughly $800, compared with about $6,200 per patient-year for clinic-administered intravenous immunoglobulin, a savings of more than $5,300 per patient per year.⁶ The researchers estimated that if 80% of patients switched to home-based subcutaneous therapy, the health system would save more than $31 million. A separate prospective economic analysis found that average hospital and physician costs were roughly $1,800 in the home subcutaneous group versus about $4,200 in the hospital intravenous group.⁷

Keep in mind that these figures focus on the administration costs, meaning nursing time, facility fees, and physician visits. The immunoglobulin product itself is expensive regardless of where or how it is infused. The drug accounts for the lion’s share of total spending, and pricing fluctuates based on global supply and demand. What home-based subcutaneous infusion does is strip away the clinic overhead and give patients autonomy. An Australian cost-utility analysis also found that home subcutaneous therapy was both cheaper overall and associated with better quality-of-life scores, making it the dominant strategy by health-economic standards.⁸

Parenteral Nutrition and Enzyme Replacement

Some patients depend on home infusion not for a medication but for nutrition delivered directly into the bloodstream. Home parenteral nutrition is used when the gut cannot absorb enough nutrients, whether because of short bowel syndrome, severe Crohn’s disease, or complications from cancer treatment. This is a long-term, high-cost therapy. A study tracking direct costs found that home parenteral nutrition averaged about €124 per patient per day, with the annual per-patient cost reaching roughly €13,400.⁹ The nutrition formulation and supplies themselves made up about three-quarters of the total cost, while managing complications accounted for about a fifth.

Enzyme replacement therapy for rare metabolic conditions is another category where home infusion has gained ground. A study comparing home-based enzyme replacement with inpatient delivery found that the mean cost per day was roughly $225 at home versus about $587 in the hospital.¹⁰ For patients who need infusions every one to two weeks for the rest of their lives, the per-day gap multiplied over years represents substantial money. Home infusion also avoids the disruption of repeated hospital visits, which for rare disease patients often means traveling to a specialty center.

What Makes Up the Bill

Understanding where the money goes helps explain why costs vary so much from one patient to the next. A typical home infusion bill has several components:

Drug cost: This is usually the largest share, especially for specialty biologics, immunoglobulins, and parenteral nutrition formulations. A single vial of some biologic drugs can cost thousands of dollars.
Nursing services: A registered nurse or infusion nurse visits to start the IV, monitor for reactions, and educate the patient. Some therapies eventually let you self-administer, cutting this cost substantially.
Supplies and equipment: IV tubing, needles, pumps, dressings, and sharps containers. For parenteral nutrition, the compounding of the solution itself is a significant line item.
Pharmacy compounding: Home infusion pharmacies prepare and deliver the medication, which involves sterile compounding, stability testing, and cold-chain delivery.
Monitoring and follow-up: Lab draws, physician check-ins, and pharmacist reviews to track how treatment is going and adjust doses.

The drug cost is the one component that stays roughly the same regardless of setting. Everything else shrinks when you move from a hospital to the home. Facility fees vanish entirely. Nursing time is often reduced because the nurse is focused on one patient rather than managing a bay of infusion chairs. And many home infusion therapies eventually transition to self-administration, eliminating routine nursing visits altogether.

The Costs You Do Not See on the Bill

The financial calculus of home infusion extends beyond the direct medical charges. For patients and families, one of the biggest hidden costs of hospital-based infusion is the time and money spent getting there. A study comparing home-based and hospital-based subcutaneous trastuzumab for breast cancer found that patient and family costs were lower at home, largely because travel expenses dropped to zero and informal caregiver time fell substantially.¹¹ Those numbers might look small on a per-visit basis, but for a patient receiving infusions every three weeks for a year, the cumulative travel expenses, parking fees, and lost wages add up.

Productivity losses are another hidden factor. If you need someone to drive you to a hospital infusion center, wait during a multi-hour appointment, and drive you home, that is a full day of lost work for two people. Home infusion compresses the disruption. The nurse arrives, runs the infusion, and leaves. Self-administered therapies are even less disruptive because you can fit them around your own schedule.

Then there is the less quantifiable cost of caregiver burden. For parents managing a child’s long-term infusion therapy or adults caring for an elderly spouse, repeated hospital trips impose a real toll. Home infusion does not eliminate the work of managing a chronic condition, but it does consolidate that work into a familiar environment where the rest of life can continue around it.

When Complications Drive Costs Back Up

Home infusion is not risk-free, and complications can erode some of the cost advantage. The most common issues involve the intravenous access device itself. PICC lines and other central venous catheters can become infected, clot off, or malfunction. One study of self-administered outpatient parenteral antibiotic therapy found that about a quarter of patients presented to the emergency department during their course of treatment, with roughly 14% presenting specifically with PICC line concerns.¹²

Catheter-related bloodstream infections are particularly expensive to treat. A single-center study found that the additional hospital stay costs attributable to peripheral venous catheter-related bacteremia were roughly €5,600 per episode.¹³ For central lines, the costs can be even higher. This is why home infusion programs invest in patient education, nursing oversight, and careful catheter care protocols. A complication that sends you back to the hospital can wipe out weeks of savings in a single admission. Still, the overall evidence suggests that complication rates are manageable and that home infusion remains cost-effective on a population basis even after accounting for these events.

Insurance Coverage and Out-of-Pocket Reality

For many patients, the most frustrating part of home infusion costs is not the total price but how much of it lands on them. Insurance coverage for home infusion is uneven and confusing. Private insurance plans often cover home infusion but may classify it differently depending on whether the drug is a pharmacy benefit or a medical benefit. That classification affects your copay, your deductible, and whether the infusion pharmacy needs prior authorization.

Medicare has historically been a problem area. Under traditional Medicare, most outpatient infusion drugs are covered under Part B when administered in a physician’s office or hospital outpatient department, but coverage for the same drug administered at home has been more limited. Some home infusion services fall under the durable medical equipment benefit, which covers the pump and supplies but has not always covered the nursing services adequately. Changes in recent years have started to expand Medicare home infusion coverage, but the benefit remains more complicated than what commercially insured patients typically navigate.

Your out-of-pocket cost also depends on where you fall in your plan’s benefit structure. A patient with a high-deductible plan receiving a specialty biologic at home could face thousands of dollars in cost-sharing early in the plan year, even though the health system is saving money by keeping them out of the hospital. Manufacturer copay assistance programs, specialty pharmacy patient support, and state-level mandates can all affect what you actually pay, but the landscape is fragmented enough that two patients on the same drug with different insurers can have wildly different experiences.

Rural Access and the Geography of Cost

Where you live affects both whether home infusion is available and what it costs. A multi-center study of home infusion providers found that only about 13% of home infusion patients lived in rural areas, despite rural populations making up a larger share of the overall population.¹⁴ Rural patients face longer delivery distances for temperature-sensitive medications, fewer available infusion nurses, and sometimes a complete absence of home infusion pharmacy services in their area.

These logistical challenges can push costs up or push patients into more expensive settings by default. If no home infusion provider services your zip code, your options narrow to driving to an infusion center, which may be hours away, or receiving treatment in a local hospital at the higher facility rate. Some specialty pharmacies have expanded cold-chain shipping to reach rural patients, but nursing coverage remains the harder problem. A pump and tubing can be shipped, but a nurse who can start your IV and monitor your first infusion has to physically be there.

White Bagging and Site-of-Service Policies

A growing trend in commercial insurance involves so-called “white bagging” and “site-of-service” policies, where insurers direct where a drug is purchased and where it is administered. Under white bagging, the insurer requires the drug to be dispensed by a specialty pharmacy and shipped to the infusion site rather than bought and billed by the provider. The stated goal is to reduce provider markup on expensive specialty drugs.¹⁵

For patients, these policies can lower costs by reducing the facility-related charges baked into hospital-administered infusions. But they also introduce complexity. If a specialty pharmacy ships your drug to your doctor’s office and the drug arrives damaged or at the wrong temperature, the infusion has to be rescheduled. Some providers have raised concerns about liability when they are administering a drug they did not purchase, store, or verify themselves. The policy debate around white bagging is still evolving, but it reflects a broader push by payers to separate the cost of the drug from the cost of the facility, which is conceptually the same thing that makes home infusion cheaper in the first place.

Why the System Has Been Slow to Shift

Given the consistent evidence that home infusion is cheaper and at least as safe as hospital-based infusion for most therapies, you might wonder why it is not the default. Part of the answer is institutional inertia: hospitals and health systems earn revenue from infusion services, and shifting those patients home reduces that revenue. Part of it is regulatory: Medicare’s historically patchy coverage of home infusion created a financial disincentive for patients and providers alike. And part of it is clinical culture. Physicians trained in hospital settings are accustomed to seeing their patients in their own infusion centers, and referring patients to a home infusion service requires trusting an external pharmacy and nursing team.

The economics of home infusion have been well documented for decades. As early as the 1990s, researchers were pointing out that home IV services had become increasingly attractive as economic constraints tightened around the healthcare system.¹⁶ More recent large-scale studies continue to show significant savings with no compromise in outcomes.¹⁷ The evidence base is not the bottleneck. What still needs to catch up is the payment infrastructure, the referral culture, and the support systems that would make home infusion accessible to a broader population, particularly in underserved and rural areas where the logistical barriers remain real.